|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Overexpressed uPA and MMP-2 are regarded as signs of malignant tumors in clinical practice.
|
31830149 |
2020 |
|
Tumor Cell Invasion
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Urokinase-type plasminogen activator (uPA) has been shown to activate matrix metalloproteinase-2 (MMP-2) that leads to the migration and invasion of breast cancer cells.
|
31830149 |
2020 |
|
Malignant neoplasm of prostate
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
To investigate the prognostic role of expression of urokinase-type plasminogen activator system members, such as urokinase-type activator (uPA), uPA-receptor (uPAR), and plasminogen activator inhibitor-1 (PAI-1), in patients treated with radical prostatectomy (RP) for prostate cancer (PCa).
|
31797075 |
2019 |
|
Prostate carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
To investigate the prognostic role of expression of urokinase-type plasminogen activator system members, such as urokinase-type activator (uPA), uPA-receptor (uPAR), and plasminogen activator inhibitor-1 (PAI-1), in patients treated with radical prostatectomy (RP) for prostate cancer (PCa).
|
31797075 |
2019 |
|
Non-metastatic prostate cancer
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Expression of urokinase-type plasminogen activator system in non-metastatic prostate cancer.
|
31797075 |
2019 |
|
Malignant tumor of colon
|
0.100 |
Biomarker
|
disease |
BEFREE |
To achieve so, we used our recently developed mouse model, in which colon cancer arises in the absence of urokinase-type plasminogen activator (uPA) due to colitis induced by dextran sodium sulfate (DSS) treatment.
|
31758376 |
2020 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Sox9 transcription factor, however, was significantly downregulated in the uPA-deficient/DSS-treated mice that developed colon adenomas as compared to the wild-type/DSS-treated group with no neoplasia identified.
|
31758376 |
2020 |
|
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
To achieve so, we used our recently developed mouse model, in which colon cancer arises in the absence of urokinase-type plasminogen activator (uPA) due to colitis induced by dextran sodium sulfate (DSS) treatment.
|
31758376 |
2020 |
|
Dejerine-Sottas Disease (disorder)
|
0.020 |
Biomarker
|
disease |
BEFREE |
Sox9 transcription factor, however, was significantly downregulated in the uPA-deficient/DSS-treated mice that developed colon adenomas as compared to the wild-type/DSS-treated group with no neoplasia identified.
|
31758376 |
2020 |
|
DOSAGE-SENSITIVE SEX REVERSAL
|
0.020 |
Biomarker
|
disease |
BEFREE |
Sox9 transcription factor, however, was significantly downregulated in the uPA-deficient/DSS-treated mice that developed colon adenomas as compared to the wild-type/DSS-treated group with no neoplasia identified.
|
31758376 |
2020 |
|
Colitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
To achieve so, we used our recently developed mouse model, in which colon cancer arises in the absence of urokinase-type plasminogen activator (uPA) due to colitis induced by dextran sodium sulfate (DSS) treatment.
|
31758376 |
2020 |
|
Congestive heart failure
|
0.020 |
Biomarker
|
disease |
BEFREE |
Soluble urokinase-type plasminogen activator receptor represents exercise tolerance and predicts adverse cardiac events in patients with heart failure.
|
31741050 |
2019 |
|
Heart failure
|
0.010 |
Biomarker
|
disease |
BEFREE |
Soluble urokinase-type plasminogen activator receptor represents exercise tolerance and predicts adverse cardiac events in patients with heart failure.
|
31741050 |
2019 |
|
cardiac event
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Soluble urokinase-type plasminogen activator receptor represents exercise tolerance and predicts adverse cardiac events in patients with heart failure.
|
31741050 |
2019 |
|
Neoplasm Metastasis
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
6-Substituted amiloride derivatives as inhibitors of the urokinase-type plasminogen activator for use in metastatic disease.
|
31679971 |
2019 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
These effects appear to arise, at least in part, through moderate inhibition of the urokinase-type plasminogen activator (uPA, K<sub>i</sub> = 2.4 µM), a pro-metastatic trypsin-like serine protease that is upregulated in many aggressive solid malignancies.
|
31679971 |
2019 |
|
Congestive heart failure
|
0.020 |
Biomarker
|
disease |
BEFREE |
Longitudinally measured PAI-1, uPA, and suPAR are strongly associated with adverse cardiac events during the course of CHF.
|
31659734 |
2019 |
|
Chronic Kidney Diseases
|
0.030 |
Biomarker
|
group |
BEFREE |
Clinical value of soluble urokinase type plasminogen activator receptors in chronic kidney disease.
|
31567954 |
2019 |
|
Hyperinsulinism
|
0.010 |
Biomarker
|
disease |
BEFREE |
LA administration did not affect strain differences under RD but attenuated αMUPA's hyperinsulinemia and DIO under HFD, most likely by mediating energy expenditure.
|
31454257 |
2019 |
|
Obesity
|
0.010 |
Biomarker
|
disease |
BEFREE |
This study therefore supports the use of αMUPA mice for elucidating developmental mechanisms of obesity and the efficacy of early-life manipulations via leptin surge axis in attenuating DIO.
|
31454257 |
2019 |
|
Quebec platelet disorder
|
0.670 |
Biomarker
|
disease |
BEFREE |
A unique gain-of-function defect in fibrinolysis causes the Quebec platelet disorder (QPD) which is characterized by profibrinolytic platelets containing increased urokinase-type plasminogen activator (uPA) in the α-granules.
|
31427261 |
2019 |
|
Hypernatremia
|
0.020 |
Biomarker
|
phenotype |
BEFREE |
Urokinase-type plasminogen activator contributes to amiloride-sensitive sodium retention in nephrotic range glomerular proteinuria in mice.
|
31423748 |
2019 |
|
Cerebrovascular accident
|
0.310 |
Biomarker
|
group |
BEFREE |
Patients with first-in-life stroke were analysed according to: plasma concentration of the following markers on the first day of stroke: interleukin 2 (IL-2) and interleuki 6 (IL-6), S100B, tumor necrosis factor-α (TNF-α), progranulin (GRN), neuron specific enolase (NSE), urokinase-type plasminogen activator (uPA), vascular endothelial growth factor (VEGF), brain-derived neurotrophic factor (BDNF), C-reactive protein (CRP), leucocyte and thrombocyte counts; their neurological status on the first day of stroke (NIHSS) and their functional status at 30 days following stroke (mRS).
|
31356182 |
2019 |
|
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
MiR-193a-3p/PLAU axis might provide a potent therapeutic opportunity for aggressive CRC.
|
31354344 |
2019 |
|
Malignant neoplasm of breast
|
0.300 |
Biomarker
|
disease |
BEFREE |
Fluid shear stress stimulates breast cancer cells to display invasive and chemoresistant phenotypes while upregulating PLAU in a 3D bioreactor.
|
31317530 |
2019 |